TrialJAMA oncology2017
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Laura J Esserman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
53 papers cite it
this paperpooled ittrialcites it